Journal of biopharmaceutical statistics · 2026
Model generalizability considerations in development and evaluation of SaMD.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Leng Ning, Lu Yichen, Fridlyand Jane, Tang Tiffany, Qi Ting, Wei Yingying, Sanchez Rodrigo Rojo, Simon Noah, Alexander Gregory
Аннотация
Software as a Medical Device (SaMD) has been transforming medical practices by improving patient care with more precise and timely information. Key capabilities of SaMD are often powered by Artificial Intelligence (AI) algorithms. However, significant challenges arise in developing robust algorithms for SaMD, as these algorithms can perform well during development but poorly during pivotal validation studies. Due to the rapid advancement in medical research, data from new studies or real-world sources are likely to differ significantly from the legacy data used for development; with this, algorithms need to account for these potential data heterogeneity differences. This paper discusses the shortcomings of conventional cross-validation methods widely used in SaMD algorithm development and demonstrates model performance overestimation in the presence of data heterogeneity. To address this bias, we propose a simple and practical alternative: the leave-one-set-out (LOSO) cross-validation method. Additionally, we outline best practices for designing independent validation pivotal studies.